SLC5A2 and fatty liver disease: Fifth, approximately half of the participants had diabetes, and some of them were treated with glucose-lowering agents including sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, which may affect hepatic steatosis.